HHSN261201400048C; TOPIC 309 ? ?DEVEL.OF.LOW COST,SMALLSAMPLE MULTI-ANAL.TECH.FORCANCER DIAGNOSIS,PROGNOSIS&EARLY DETECTION?;TITLE: DEPLOYMENT.OF.PROTOTYPE SYSTEM FOR DETECTION OF MULTI. ANAL. IN SMAL

这项提议将建立在第一阶段的成功努力的基础上，这一阶段的努力有助于描述该技术的 检测的准确性和限度，并对患者的粘膜活检样本提供概念数据的证据 患有结直肠癌。我们的目标是(1)开发一个原型分析系统 技术，包括自动化、软件和数据分析以及(2)#年临床样本的测试原型 与学术实验室合作，展示与分析电流相比的临床实用性和优势 技巧。 我们的合作者包括Jedd Wolchok(纪念斯隆·凯特琳癌症中心)，他领导了 突破性的癌症免疫疗法ipilimumab和nivolumab，Douglas Kuan(Ragon Institute)，其实验室 拥有粘膜免疫学方面的专业知识，并对Enumber的技术有丰富的经验；伊丽莎白·希尔曼 (哥伦比亚大学)，在开发新型光学成像系统方面拥有专业知识；Jason Ruan(VigeneTech) 他是图像分析和软件开发方面的专家，Paul和Doug Sabin(Fikst)是专家 在产品开发方面。 利用Enumber的平台了解常驻组织的细胞功能和对治疗的反应可以 可能会对癌症的早期诊断、疾病机制的理解产生重大影响 进展，并最终开发新的、有效和安全的免疫疗法。

This proposal will build on the successful efforts from Phase I, which served to characterize the technology's accuracy and limits of detection and provide proof of concept data on mucosal biopsy samples from patients with colorectal cancer. We aim to (1) Develop a prototype analytical system incorporating Enumeral's technology, including automation, software and data analysis and (2)Test prototypes on clinical samples in collaborating academic laboratories to demonstrate clinical utility and advantages over analytical current techniques. Our collaborators include Jedd Wolchok (Memorial Sloan Kettering Cancer Center), who led clinical efforts for breakthrough cancer immunotherapies ipilimumab and nivolumab, Douglas Kwon (Ragon Institute), whose lab has expertise in mucosal immunology and extensive experience with Enumeral's technology; Elizabeth Hillman (Columbia University), who has expertise in developing novel optical imaging systems; Jason Ruan (VigeneTech) who is an expert in image analysis and software development, and Paul and Doug Sabin (Fikst) who are experts in produce development. The use of Enumeral's platform to understand cellular function and responses to therapy in resident tissues can potentially have a significant impact on early cancer diagnosis, understanding mechanisms of disease progression, and, ultimately development of novel, effective, and safe immunotherapies.